Indication: Animal cancer - multiple tumour types
Technology Platform: Autologous (personalised) cancer vaccine

Product pipeline

The progression of Kvax through the Regeneus pipeline

Kvax is a vaccine manufactured from a patient’s own cancer cells and is designed to activate the immune system against the cancer cells to initiate a systemic immune response and to effectively fight the cancer cells.

Kvax is currently being evaluated in a clinical trial for the use of Kvax in combination with chemotherapy for the treatment of canine lymphoma. For further information on this clinical trial, please refer to our Trials page.

Points of difference

Autologous cancer vaccines have been studied previously and reveal a favourable side effect profile when compared to traditional chemotherapy and recent immunotherapies such as monoclonal antibodies. Autologous vaccines work to stimulate the body’s immune system to attack the tumour proteins and is therefore a more gradual and ‘gentle’ mechanism than standard chemotherapy, which is designed to be toxic to all rapidly growing cells in the body.

Autologous vaccines offer a patient specific, personalised treatment that contains the right mix of tumour associated antigens (TAAs) for the body to recognise and attack; The benefit of the animal cancer vaccine is its ability to accurately match the circulating and existing tumour cells in a patient's body. Multiple treatment courses can be manufactured per patient tumour sample.

Kvax has been used to treat a wide number of different tumour types; with proven safety in clinical studies in dogs. Kvax has been given regulatory clearance for commercial use in the US and Australia. The Kvax manufacturing process is simple and rapid and many vaccines can be products from a single donor.

Next steps for Kvax

In 2015 we completed a small osteosarcoma trial conducted by Phil Bergman at VCA in the US. The trial evaluated the safety, tolerability and preliminary efficacy of Kvax and we will report on the results in Q2 FY17.

We are actively exploring a commercial partner to take up the sales and marketing rights for Kvax.

Related ASX announcements